SEARCH

SEARCH BY CITATION

References

  • 1
    Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, J Viral Hepatol 1999; 6: 3547.
  • 2
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556562.
  • 3
    Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 18991905.
  • 4
    National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 Gastroenterology 2002; 123: 20822099.
  • 5
    Pearlman BL. Hepatitis C treatment update. Am J Med 2004; 117: 344352.
  • 6
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a complementary DNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359362.
  • 7
    Lohmann V, Korner F, Herian U, Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997; 71: 84168428.
  • 8
    Tomei L, Vitale RL, Incitti I, Serafini S, Altamura S, Vitelli A, et al. Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. J Gen Virol 2000; 81: 759767.
  • 9
    Ferrari E, Wright-Minogue J, Fang JW, Baroudy BM, Lau JY, Hong Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J Virol 1999; 73: 16491654.
  • 10
    Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999; 6: 937943.
  • 11
    O'Farrell D, Trowbridge R, Rowlands D, Jager J. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J Mol Biol 2003; 326: 10251035.
  • 12
    Biswal BK, Cherney MM, Wang M, Chan L, Yannopoulos CG, Bilimoria D, et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J Biol Chem 2005; 280: 1820218210.
  • 13
    Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110113.
  • 14
    Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 19721974.
  • 15
    Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927933.
  • 16
    Walker CM. Comparative features of hepatitis C virus infection in humans and chimpanzees. Springer Semin Immunopathol 1997; 19: 8598.
  • 17
    Kneteman NM, Weiner AJ, O'Connell J, Collett M, Gao T, Aukerman L, et al. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. HEPATOLOGY 2006; 43: 13461353.
  • 18
    Howe AY, Bloom J, Baldick CJ, Benetatos CA, Cheng H, Christensen JS, et al. Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2004; 48: 48134821.
  • 19
    Howe A, Cheng H, Johann S, Mullen S, Chunduru SK, Young DC, et al. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother. 2008; 52: 33273338.
  • 20
    Chandra P RD, Moyer L, Harper D, et al. Safety and pharmacokinetics of the non-nucleoside polymerase inhibitor, HCV-796: results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects. European Association for the Study of Liver (EASL) 2006.
  • 21
    Villano S, Howe A, Raible D, Harper D, Speth J, Bichier G, et al. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients [Abstract]. HEPATOLOGY 2006; 44( Suppl 1): 607A608A.
  • 22
    Villano SA, Raible D, Harper D, Speth J, Chandra P, Shaw P, et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alfa-2b in treatment-naive patients with chronic HCV. J Hepatol 2007; 46( Suppl 1): S24.
  • 23
    Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003; 100: 72717276.
  • 24
    Kato T, Date T, Miyamoto M, Zhao Z, Mizokami M, Wakita T. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 2005; 79: 592596.
  • 25
    Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791796.
  • 26
    Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005; 102: 92949299.
  • 27
    Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623626.
  • 28
    Shindo M, Di Bisceglie AM, Biswas R, Mihalik K, Feinstone SM.. Hepatitis C virus replication during acute infection in the chimpanzee. J Infect Dis 1992; 166: 424427.
  • 29
    Galun E, Burakova T, Ketzinel M, Lubin I, Shezen E, Kahana Y, et al. Hepatitis C virus viremia in SCID–>BNX mouse chimera. J Infect Dis 1995; 172: 2530.
  • 30
    Xie ZC, Riezu-Boj JI, Lasarte JJ, Guillen J, Su JH, Civeira MP, et al. Transmission of hepatitis C virus infection to tree shrews. Virology 1998; 244: 513520.
  • 31
    Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990; 62: 447456.
  • 32
    Rhim JA, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Replacement of diseased mouse liver by hepatic cell transplantation. Science 1994; 263: 11491152.
  • 33
    Rhim JA, Sandgren EP, Palmiter RD, Brinster RL. Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc Natl Acad Sci U S A 1995; 92: 49424946.
  • 34
    Gopalsamy A, Lim K, Ciszewski G, Park K, Ellingboe JW, Bloom J, et al. Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors. J Med Chem 2004; 47: 66036608.
  • 35
    Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186189.
  • 36
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral activity of interferon alpha therapy. Science 1998; 282: 103107.
  • 37
    Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007; 186: 146151.
  • 38
    Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3–4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother 2006; 50: 18131822.
  • 39
    Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 12701278.